Financière de Tubize SA

ENXTBR:TUB Stock Report

Market Cap: €6.1b

Financière de Tubize Past Earnings Performance

Past criteria checks 3/6

Financière de Tubize's earnings have been declining at an average annual rate of -25%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 56.4% per year.

Key information

-25.0%

Earnings growth rate

-17.4%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate56.4%
Return on equity4.8%
Net Marginn/a
Next Earnings Update02 Aug 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Financière de Tubize makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTBR:TUB Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2409000
31 Mar 2408900
31 Dec 2308800
30 Jun 23032-10
31 Mar 2305800
31 Dec 2208500
30 Sep 2205400
30 Jun 22032010
31 Mar 22035010
31 Dec 2108400
30 Sep 21021010
30 Jun 21033620
31 Mar 21029820
31 Dec 20026120
30 Sep 20026320
30 Jun 20026610
31 Mar 20027510
31 Dec 19028410
30 Sep 19025910
30 Jun 19023510
31 Mar 19026010
31 Dec 18028510
30 Sep 18030710
30 Jun 18032910
31 Mar 18030810
31 Dec 17028610
30 Sep 17025710
30 Jun 17022910
31 Mar 17020510
31 Dec 16018100
30 Sep 16020500
30 Jun 16022900
31 Mar 16022100
31 Dec 15021300
30 Sep 15016100
30 Jun 15010910
31 Mar 1508510
31 Dec 1406100
30 Sep 1406600
30 Jun 1407100
31 Mar 1405810

Quality Earnings: TUB has high quality earnings.

Growing Profit Margin: Insufficient data to determine if TUB's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TUB's earnings have declined by 25% per year over the past 5 years.

Accelerating Growth: TUB's earnings growth over the past year (183.4%) exceeds its 5-year average (-25% per year).

Earnings vs Industry: TUB earnings growth over the past year (183.4%) exceeded the Pharmaceuticals industry 9.5%.


Return on Equity

High ROE: TUB's Return on Equity (4.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Financière de Tubize SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marc DebrouwerDegroof Petercam